Registration Is Now Open For Tribe Public's CEO Presentation and Q&A Webinar Event "A New Approach to Advanced Parkinson's Disease: Serina Discusses SER-252's Clinical Progress"

Featuring Serina Therapeutics' CEO - Thursday, September 24, 2026 10M people in the world currently living with Parkinson's disease with no major clinical advances in 50+ years Meet with Serina's CEO Steven Ledger Register at AdvancingParkinsonsDisease.TribePublic.com HUNTSVILLE, AL, Sept. 23, 2026 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. (“Serina”) (NYSE American: SER), a clinical-stage biotechnology company developing its proprietary POZ Platform™ drug optimization technology enabling drug product candidates to treat neurological diseases and other indications, is pleased to announce that Serina's CEO, Steven Ledger will present at Tribe Public's Webinar Presentation and Q&A Event titled "A New Approach to Advanced Parkinson's Disease: Serina Discusses SER-252's Clinical Progress.

GlobeNewsWire • Sep 23, 2026

Serina Therapeutics to Present at the H.C. Wainwright 28th Annual Global Investment Conference

HUNTSVILLE, AL, Sept. 10, 2026 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. (“Serina” or the “Company”) (NYSE American: SER), a clinical-stage biotechnology company developing its proprietary POZ Platform™ drug optimization technology enabling drug product candidates to treat neurological diseases and other indications, today announced that Steve Ledger, Chief Executive Officer, will present at the upcoming H.C. Wainwright 28th Annual Global Investment Conference. The Company will also attend one-on-one investor meetings during the conference taking place September 14-16, 2026 in New York, New York.

GlobeNewsWire • Sep 10, 2026

Serina Therapeutics Reports Cohort 1 Observations from SER-252 Registrational Study in Advanced Parkinson's Disease and Advances to Cohort 2

- Independent Safety Monitoring Committee recommends advancement to Cohort 2 following blinded review of Cohort 1 safety and tolerability data –  - Pharmacokinetic observations at the lowest dose evaluated were consistent with the sustained apomorphine exposure SER-252 is designed to provide – - Blinded Cohort 1 observations included sustained periods of improvement in motor function in individual patients on exploratory clinical measures – - Serina expects to report topline data from the single-ascending-dose portion of the study in the first half of 2027 - HUNTSVILLE, Ala., Sept. 09, 2026 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. (“Serina” or the “Company”) (NYSE American: SER), a clinical-stage biotechnology company developing its proprietary POZ Platform™ drug optimization technology, today announced that the independent Safety Monitoring Committee (SMC) has completed its blinded review of Cohort 1 of the ongoing Phase 1b registrational study of SER-252 in patients with advanced Parkinson's disease and recommended that the study advance to Cohort 2.

GlobeNewsWire • Sep 9, 2026

Serina Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Updates

HUNTSVILLE, Aug. 13, 2026 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. (“Serina” or the "Company") (NYSE American: SER), a clinical-stage biotechnology company developing its proprietary POZ Platform™ drug optimization technology, today reported its financial results for the second quarter ended June 30, 2026, along with key business updates.

GlobeNewsWire • Aug 13, 2026

Serina Therapeutics to Participate in the BTIG Virtual Biotechnology Conference

HUNTSVILLE, Ala., July 24, 2026 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. (“Serina” or the “Company”) (NYSE American: SER), a clinical-stage biotechnology company developing its proprietary POZ Platform™ drug optimization technology, today announced that management will participate in the BTIG Virtual Biotechnology Conference, taking place July 28-29, 2026.

GlobeNewsWire • Jul 24, 2026

Serina Therapeutics Announces Completion of Enrollment and Dosing in Cohort 1 of Registrational Trial of SER-252 for Advanced Parkinson's Disease

- All eight patients enrolled and dosed in Cohort 1 ahead of previously disclosed guidance of the end of the third quarter of 2026 - - Independent Safety Monitoring Committee to review Cohort 1 safety and tolerability in accordance with the study protocol - - Company expects to provide a further update following completion of the Safety Monitoring Committee review – HUNTSVILLE, Ala., July 23, 2026 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. (“Serina” or the "Company") (NYSE American: SER), a clinical-stage biotechnology company developing its proprietary POZ Platform™ drug optimization technology, today announced the completion of enrollment and dosing in Cohort 1 of its ongoing Phase 1b registrational clinical trial evaluating SER-252 in patients with advanced Parkinson's disease.

GlobeNewsWire • Jul 23, 2026

Serina Therapeutics Appoints Farrell Simon to its Board of Directors

HUNTSVILLE, Ala., July 22, 2026 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. (“Serina” or the “Company”) (NYSE American: SER), a clinical-stage biotechnology company advancing its proprietary POZ Platform™ drug optimization technology, today announced the appointment of Farrell Simon, Pharm. D., to its Board of Directors, effective immediately. Dr. Simon will also serve on the Board's Audit and Compensation Committees.

GlobeNewsWire • Jul 22, 2026

Serina Therapeutics Announces Completion of Sentinel Dosing in Cohort 1 of Phase 1b Registrational Trial of SER-252 for Advanced Parkinson's Disease

HUNTSVILLE, Ala., July 09, 2026 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. (“Serina” or the "Company") (NYSE American: SER), a clinical-stage biotechnology company developing its proprietary POZ Platform™ drug optimization technology, today announced the completion of sentinel dosing in Cohort 1 of its ongoing Phase 1b registrational clinical trial evaluating SER-252 in patients with advanced Parkinson's disease.

GlobeNewsWire • Jul 9, 2026

Gannet BioChem and Serina Therapeutics Enter Development Partnership Supporting SER-252 Program

HUNTSVILLE, Ala., June 30, 2026 (GLOBE NEWSWIRE) -- Gannet BioChem , a leading life sciences manufacturing company, today announced a development partnership with Serina Therapeutics, Inc. (NYSE American: SER), a clinical-stage biotechnology company advancing therapies enabled by its proprietary POZ Platform™ technology.

GlobeNewsWire • Jun 30, 2026

Serina Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Updates

Phase 1b Registrational Clinical Study of SER-252 Underway in Advanced Parkinson's Disease; TFL data from the SAD study arm targeted for first half of 2027 -

GlobeNewsWire • May 14, 2026